tiprankstipranks
Advertisement
Advertisement

IKT Stock Latest News

Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum
RatingsAnalyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum
2d ago
IKT
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
PremiumCompany Announcements
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
4d ago
8K
IKT
Inhibikase Gains FDA Orphan Drug Status for IKT-001
PremiumCompany Announcements
Inhibikase Gains FDA Orphan Drug Status for IKT-001
10d ago
8K
IKT
Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
PremiumThe Fly
Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
10d ago
IKT
Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation
PremiumThe Fly
Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation
17d ago
IKT
Inhibikase raises $50M to fund PAH program
PremiumCompany AnnouncementsInhibikase raises $50M to fund PAH program
18d ago
8K
IKT
Inhibikase Shareholders Approve Governance and Compensation Changes
Premium
Company Announcements
Inhibikase Shareholders Approve Governance and Compensation Changes
1M ago
8K
IKT
Inhibikase Therapeutics initiated with an Outperform at Oppenheimer
Premium
The Fly
Inhibikase Therapeutics initiated with an Outperform at Oppenheimer
2M ago
IKT
Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
PremiumRatings
Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
2M ago
IKT
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
PremiumCompany Announcements
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
3M ago
IKT
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
PremiumCompany Announcements
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
3M ago
IKT
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
PremiumRatings
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
4M ago
IKT
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
PremiumRatingsInhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
4M ago
IKT
Inhibikase Begins Pivotal Phase 3 Trial in PAH
Premium
Company Announcements
Inhibikase Begins Pivotal Phase 3 Trial in PAH
4M ago
8K
IKT
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
Premium
The Fly
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
4M ago
IKT
IKT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
IKT Upcoming Earnings Report: What to Expect?
4M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
5M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
5M ago
IKT
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
PremiumRatings
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
5M ago
IKT
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
PremiumMarket NewsBank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
5M ago
IKT
WVE
Inhibikase Therapeutics initiated with a Buy at BofA
Premium
The Fly
Inhibikase Therapeutics initiated with a Buy at BofA
6M ago
IKT
Dynavax, Inhibikase and More: Stocks Trending by Analysts
Premium
Weekend Updates
Dynavax, Inhibikase and More: Stocks Trending by Analysts
7M ago
IKT
DVAX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >